Research programme: gold nanoparticle based therapy - Oraya Therapeutics

Drug Profile

Research programme: gold nanoparticle based therapy - Oraya Therapeutics

Alternative Names: Gold nanoparticles - Oraya Therapeutics

Latest Information Update: 27 Nov 2014

Price : $50

At a glance

  • Originator Oraya Therapeutics
  • Developer Dana-Farber Cancer Institute; Oraya Therapeutics
  • Class Heavy metals
  • Mechanism of Action Angiogenesis inhibitors; Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Research Wet age-related macular degeneration

Most Recent Events

  • 05 Aug 2014 Early research in Wet age-related macular degeneration in USA (IV)
  • 05 Aug 2014 Oraya Therapeutics receives Small Business Technology Transfer grant from NIH for the development of gold nanoparticles in Wet age-related macular degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top